Department of Pharmacology, L.M. College of Pharmacy, Navrangpura, Ahmedabad-3800 09 Gujarat, India.
Pharmacol Rep. 2011;63(3):629-42. doi: 10.1016/s1734-1140(11)70575-8.
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including rugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease.
炎症性肠病（IBD）是一种胃肠道慢性炎症性疾病，包括克罗恩病（CD）和溃疡性结肠炎（UC）。这些疾病已成为重要的健康问题。在过去十年中，随着靶向生物疗法的引入、旧疗法的优化，包括免疫调节剂和 5-氨基水杨酸（5-ASA）等药物，以及对黏膜免疫系统和涉及 IBD 发病机制的遗传学的更好理解，IBD 的医学治疗取得了显著进展。IBD 治疗的目标是诱导和维持缓解。目前的治疗模式涉及逐步升级的方法，仅在较温和、潜在副作用较少的治疗方法失败或患者认为自己患有侵袭性疾病时，才使用更积极、更有效的治疗方法。本文重点介绍炎症性肠病的当前治疗方法。
